SEC13DSPECIAL SITUATIONS RESEARCHContact us →
SPECIAL SITUATIONSSource-linked research across special situationsCoverage & limitations →
← All situations
INCYcompletedTender offer

Incyte Corporation

Tender completed · Biopharmaceuticals

Reviewed research · How it works →
Sources throughJun 13, 2024
Last source checkNot published
Research updatedSep 26, 2026

LATEST DEVELOPMENT

The final results state that 29,821,563 shares were properly tendered at or below $60 and that Incyte accepted 27,866,666 shares at $60 for approximately $1.672 billion, excluding fees and expenses.

Offeror
Incyte Corporation [1]
Offer mechanism
Issuer modified Dutch auction [1]

POST-EVENT FOLLOW-UP

Capital allocation and post-repurchase share-count disclosure

Next periodic capital-allocation update

Inspect 2 source documents →

What happened

Incyte launched an issuer modified Dutch auction for up to $1.672 billion of common stock at $52 to $60 per share, funded with cash on hand and scheduled to expire at midnight at the end of June 10, 2024, New York City time. The final results state that 29,821,563 shares were properly tendered at or below $60 and that Incyte accepted 27,866,666 shares at $60 for approximately $1.672 billion, excluding fees and expenses.

Why it matters

Research interpretation · Reviewed

The clearing price at the top of the offered range and accepted amount below shares tendered indicate strong participation relative to the fixed dollar cap. With the issuer offer complete, the research question moves from tender mechanics to the effect of the repurchase and related Baker Entities purchase on liquidity, ownership concentration, per-share metrics and future business-development capacity.

Open questions

  • What is the final fully diluted share-count effect after the related Baker Entities purchase?
  • How does management balance future pipeline investment and capital returns after the cash outlay?
  • Will the repurchase materially change ownership concentration or trading liquidity?

Key risks

  • The combined cash outlay may reduce flexibility for acquisitions, pipeline investment or later repurchases.
  • The related Baker Entities purchase needs to be evaluated together with the issuer tender when assessing ownership and share-count effects.
  • Headline accretion can obscure changes in balance-sheet resilience.

Key disclosed facts

Offeror
Incyte Corporation Source 1
Offer mechanism
Issuer modified Dutch auction Source 1
Price / range
$60 final purchase price Source 2
Expiration and timezone
12:00 midnight, end of June 10, 2024, New York City time Source 2

Source evidence

Inspect the excerpt or open the original filing for its full context.

SOURCE 1 · SC TO-IMay 13, 2024

SC TO-I · May 13, 2024 · Original filing ↗

Read source excerpt
Exhibit (a)(5)(B) Notice of Offer to Purchase for Cash by Incyte Corporation of Up to $1.672 Billion in Value of Its Common Stock at a Purchase Price Not Greater Than $60.00 Per Share Nor Less Than $52.00 Per Share Incyte Corporation, a Delaware corporation (the “Company”), is offering to purchase for cash up to $1.672 billion in value of shares of its common stock, $.001 par value (the “shares”), through a modified “Dutch auction” tender offer, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated May 13, 2024 (the “Offer to Purchase”), and in the related Letter of Transmittal (which together, as they may be amended and supplemented from time to time, constitute the “Offer”). The Company is inviting its stockholders to tender their shares at a price not greater than $60.00 per share nor less than $52.00 per share, net to the seller in cash, less any applicable withholding taxes and without interest, upon the terms and subject to the conditions of the
SOURCE 2 · SC TO-I/AJun 13, 2024

SC TO-I/A · Jun 13, 2024 · Original filing ↗

Read source excerpt
Exhibit (a)(5)(D) Incyte Announces Final Results of Tender Offer WILMINGTON, Del. – June 13, 2024 – Incyte Corporation (Nasdaq: INCY) (“Incyte” or the “Company”) announced today the final results of its modified “Dutch auction” tender offer to purchase up to $1.672 billion in value of shares of its common stock, which expired at 12:00 midnight, at the end of the day, New York City time, on June 10, 2024. Based on the final count by Computershare Trust Company, N.A., the depositary for the tender offer, a total of 29,821,563 shares of Incyte’s common stock were properly tendered and not properly withdrawn at or below the purchase price of $60.00 per share. Incyte has accepted for purchase 27,866,666 shares of its common stock at a purchase price of $60.00 per share, for a total cost of approximately $1.672 billion, excluding fees and expenses relating to the tender offer. These shares represent appr

Research revisions

Changes to this research record. Publication dates are separate from company event dates.

New research · Revision 1

Research first published

Research publication history

When SEC13D published or maintained this record.

Research first published

Publish the reviewed Incyte Dutch auction terms, final results and related ownership questions.

Something needs a closer look?

Send the case name and the source behind your correction.

Email a correction →

For informational research purposes only. Not investment advice. Verify material facts in the full source documents.